Hum Vaccin Immunother . Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France - FluTrackers News and Information

Do not take medical advice from the internet. If you have any medical questions please consult your medical practitioner.

LATEST POSTS - click HERE

Check out the FAQ,Terms of Service & Disclaimers by clicking the link. Please register to be able to post. By viewing this site you are agreeing to our Terms of Service and Acknowledge our Disclaimers.

FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.

We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Announcement

Collapse

No announcement yet.

Hum Vaccin Immunother . Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Collapse

X

Collapse

Posts

Latest Activity

Photos

Page of 1

Filter

Time

All Time Today Last Week Last Month

Show

All Discussions only Photos only Videos only Links only Polls only Events only

Filtered by:

Clear All

new posts

Previous template Next

tetano

Editor, Senior Moderator

Join Date: Dec 2009

Posts: 111025

Share

Tweet

#1

Hum Vaccin Immunother . Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

August 16, 2024, 02:25 AM

Hum Vaccin Immunother

. 2024 Dec 31;20(1):2387221.
doi: 10.1080/21645515.2024.2387221. Epub 2024 Aug 14. Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Paul Loubet¹, Benjamin Gaborit², Mathilde Salpin³, Hèlene Gardeney⁴, Ilies Benotmane⁵, Thomas Systchenko⁴

Affiliations
PMID: 39143811

DOI: 10.1080/21645515.2024.2387221

Abstract

France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.

Keywords: COVID-19; immunocompromised; prophylaxis.

Tags: None

Previous template Next

Help

Contact Us

Go to top

Powered by vBulletin® Version 5.7.5
Copyright © 2026 MH Sub I, LLC dba vBulletin. All rights reserved.

All times are GMT-5. This page was generated at 11:10 PM.

Working...

X